Walmart Borrows $16 Billion in Second-Largest Bond Sale of Year
(Bloomberg) -- Walmart Inc. sold $16 billion of bonds to help finance its investment in India's biggest online seller, in the second-largest U.S. corporate debt sale of the year.
The retailer offered fixed- and floating-rate notes in nine parts. The longest bond, a 30-year security, yields 1.05 percentage points above Treasuries, less than the initial 1.2 percentage points that was being pitched earlier in the day, according to a person with knowledge of the matter, who asked not to be identified because the details are private. The deal edged out an offering Bayer AG completed two days ago.
Walmart, the world's largest retailer, said last month it will acquire a 77 percent stake in Flipkart Group for $16 billion, leaving the remainder to Flipkart co-founder Binny Bansal and other shareholders. The deal -- Walmart's largest ever -- gives it greater access to India's fast-growing e-commerce market as the company tries to challenge Amazon.com Inc. Walmart acquired online seller Jet.com Inc. for about $3.3 billion in 2016.
Just a week before Walmart announced its plans for a stake in Flipkart, it agreed to sell a controlling stake of its of its British business, Asda, to a competitor for $10 billion. The sale reflects Chief Executive Officer Doug McMillon's strategy to focus on high-potential markets, such as China and India.
The mega bond issue follows a $15 billion offering from Bayer, which now becomes the year's third-largest bond sale. Both trail CVS Health Corp., which sold $40 billion of bonds in March to help fund its acquisition of Aetna Inc.
All three sales are just the latest examples of what's become a growing trend in the investment-grade bond market: companies loading up on debt to fund an acquisition, and willing to sacrifice their credit ratings in the process. That's shifted the majority of investment-grade debt to land in the BBB space, according to Bloomberg Barclays index data, which could spark a wave of fallen angels into the high-yield universe when the credit cycle turns.
Potential Downgrade
The Flipkart acquisition has drawn heavy skepticism from Wall Street, prompting several equity analysts to either cut their price target for Walmart's stock or place it under review. S&P Global Ratings said there's about a 33 percent chance it may downgrade Walmart's AA rating in the next two years due to the company's “aggressive global deal-making” as it tries to compete with Amazon.
Leverage will rise to about 2 times Ebitda -- earnings before interest, tax, depreciation and amortization -- and debt will jump by more than $10 billion. Before the Flipkart deal was announced, S&P had anticipated the company would pare its debt by $5 billion. Walmart also plans to continue its current share buyback program, indicating a “potentially less conservative financial policy” going forward, S&P analyst Diya Iyer said in a May 9 report.
Moody's Investors Service, which rates both Walmart and its new bonds Aa2, an equivalent level to S&P's, has been more positive, applauding Walmart's “historically flexible” financial policy.
“We continue with our credit positive view that Flipkart represents a significant long-term opportunity for Walmart as it recalibrates its international strategy to focus on growth markets,” Moody's analyst Charlie O'Shea said in a statement Wednesday.
Barclays Plc, Citigroup Inc., JPMorgan Chase & Co., Bank of America Corp., HSBC Holdings Plc and Wells Fargo & Co. managed the bond sale, according to the filing.
--With assistance from Allan Lopez and Matthew Boyle.
To contact the reporter on this story: Molly Smith in New York at msmith604@bloomberg.net
To contact the editors responsible for this story: Nikolaj Gammeltoft at ngammeltoft@bloomberg.net, Shannon D. Harrington, Dan Wilchins
©2018 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.